期刊文献+

强直性脊柱炎合并骨髓增生异常综合征二例 被引量:3

原文传递
导出
摘要 例1男,30岁。因“双髋部交替性疼痛15年,画黄、乏力14年,发热2个月”于2008年11月20日入院。患者15岁出现双髋部交替性疼痛,
出处 《中华风湿病学杂志》 CAS CSCD 北大核心 2010年第12期853-854,共2页 Chinese Journal of Rheumatology
  • 相关文献

参考文献14

  • 1杨春花,黄烽,赵绵松,古洁若,张汉伟,余得恩.基质金属蛋白酶-3与强直性脊柱炎疾病活动相关性研究[J].中华风湿病学杂志,2004,8(10):577-582. 被引量:14
  • 2潘建玲,于威,蒲米娜.强直性脊柱炎合并急性早幼粒细胞白血病1例[J].黑龙江医学,2001,25(8):635-635. 被引量:7
  • 3张瑾.慢性粒细胞白血病并发强直性脊柱炎1例[J].临床血液学杂志,2005,18(2):128-128. 被引量:5
  • 4Wick RR,Atkinson MJ,Nekolla EA.Incidence of leukaemia and other malignant diseases following injections of the shortlived alpha-emitter 224Ra into man.Radiat Environ Biophys,2009,48:287-294.
  • 5Smith PG.The 1957 MRC report on leukaemia and aplastic anaemia in patients irradiated for ankylosing spondylitis.J Radiol Prot,2007,27:B3-B14.
  • 6Bakland G,Nossent H.Acute myelogenous leukaemia following etanercept therapy.Rheumatology (Oxford),2003,42:900-901.
  • 7Nair B,Raval G,Mehta P.TNF-alpha inhibitor etanercept and hematologic malignancies:report of a case and review of the literature.Am J Hematol,2007,82:1022-1024.
  • 8Aksu K,Donmez A,Ertan Y,et al.Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis.Rheumatol Int,2007,28:185-187.
  • 9Kemta-Lekpa F,Zahra K,Pautas C,et al.Acute myeloid leukemia after infliximab:a case report.Clin Exp Rheumatol,2009,27:999-1000.
  • 10Askling J,Klareskog L,Blomqvist P,et al.Risk for malignant lymphoma in ankylosing spondylitis:a nationwide Swedish casecontrol study.Ann Rheum Dis,2006,65:1184-1187.

二级参考文献14

  • 1Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanereept) down- regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. Rheumatology (Oxford), 2002,41: 484-489.
  • 2Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath ankylosing spondylitis functional index. J Rheumatol,1994,21: 2281-2285.
  • 3Ribbens C, Andre B, Kaye O, et al. Synovial fluid matrix metalloproteinase-3 levels are increased in inflammatory arthritides whether erosive or not. Rheumatology (Oxford), 2000,39: 1357-1365.
  • 4Granfors K, Marker-Hermann E, de Keyser F, et al. The cutting edge of spondylarthropathy research in the millennium. Arthritis Rheum, 2002,46: 606-613.
  • 5Matsui Y, Maeda M, Nakagami W, et al. The involvement of matrix metalloproteinases and inflammation in lumbar disc herniation. Spine, 1998, 23:863-869.
  • 6Luc G, Bard JM, Juhan-Vague I, et al. C-reactive protein,interleukin-6, and fibrinogen as predictors of coronary heart disease: the prime study. Arterioscler Thromb Vasc Biol, 2003,23: 1255-1261.
  • 7Garrett S, Jenkinson TR, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath AS disease activity index. J Rheumatol, 1994, 21:2286-2291.
  • 8Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol, 2002,29: 959-965.
  • 9Gu J, Marker-Hermann E, Baeten D, et al. A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients. Rheumatology (Oxford), 2002, 41:759-766.
  • 10Saraux A, Guedes C, Allain J, et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rheumatologie de I'Ouest. J Rheumatol, 1999, 26: 2622-2627.

共引文献22

同被引文献32

引证文献3

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部